MET and cholangiocarcinoma: In CCA cell lines and in vivo studies, the selective cMet inhibitor capmatinib inhibited cMet phosphorylation and activation of key downstream effectors of cMet, and as a result inhibits cell proliferation and migration and induces apoptosis (2).